Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04924803 · ClinicalTrials.gov registry record · NA
Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
A NA study of COVID-19, sponsored by NDRI-USA.
- Active
- Registry status
- NA
- Development phase
- 545
- Enrollment target
- 1
- Study location
NCT04924803: Active NA study of COVID-19, sponsored by NDRI-USA.
NCT04924803 is a NA study of COVID-19 that is active but no longer recruiting, run by NDRI-USA. The registered enrollment target is 545 participants, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04924803, a NA study of COVID-19, is active but no longer recruiting, sponsored by NDRI-USA.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 545 participants
- Enrollment target
- 1
- Study location
Study Summary
People who inject drugs (PWID) experience disproportionate risk of being infected with SARS-CoV-2, the virus that causes COVID-19, yet due to stigma, fear of mistreatment, and other factors, PWID are far less likely to be vaccinated compared to other populations. In response, we propose to continue our collaboration with a prominent community based organization serving African American and Latino PWID. Our project will explore baseline hesitancy to vaccinate among PWID, identify barriers to vaccination, and then develop and evaluate messaging designed to increase COVID-19 vaccination among our target population of PWID through a clinical trial.
Primary Outcome
Did the participant vaccinate when offered?
Conditions Studied
Interventions
- BEHAVIORAL No video
- BEHAVIORAL Video Text
Study Locations (1)
New York
- OnPoint NYC - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2026-02-27 |
| Phase | NA |
What the registry record for NCT04924803 still lists
NCT04924803 is an interventional study that assigns participants to a tested intervention. The registered 545 participants enrollment target is mid-sized for trials with a published cap, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which No video is the first listed.
NCT04924803 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04924803 about?
NCT04924803 is a clinical study titled "Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs". People who inject drugs (PWID) experience disproportionate risk of being infected with SARS-CoV-2, the virus that causes COVID-19, yet due to stigma, fear of mistreatment, and other factors, PWID are far less likely to be vaccinated compared to other populations. In response, we propose to continue ...
What is the current status of trial NCT04924803?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 545 participants. The study started on 2022-06-21. Estimated completion is 2026-02-27.
What conditions does trial NCT04924803 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04924803?
The interventions under investigation include: No video (BEHAVIORAL), Video Text (BEHAVIORAL).
Who is sponsoring clinical trial NCT04924803?
This trial is sponsored by NDRI-USA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04924803 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04924803's enrollment target sits among peer trials
545 106th of 298 higher than 193 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04553523 · 545 participants · NA
Hydrus® Microstent New Enrollment Post-Approval Study
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI